HepatoChem and XenoTech Announce Exclusive Partnership

 

Lenexa, KS, August 19th, 2014 — XenoTech announces an exclusive partnership with HepatoChem to offer fast and cost-effective metabolite production from bioactive small molecules. Based on an innovative and proprietary chemistry platform, the technology enables convenient and timely assessment of critical metabolite and toxicity issues. According to XenoTech’s Vice President of Commercial Operations, Christian Darabant, “the value of rapid metabolite synthesis for assessing clinical risk can be measured directly by comparison with the approximate $2 million per day cost impact of each day of delay in a drug’s development.”
Metabolite synthesis is critical in the drug development process as it allows researchers to accurately evaluate metabolites in safety toxicity as well as promoting identification and isolation of pharmacologically active metabolites. According to Marc Bazin, HepatoChem’s CEO, “current technologies are designed to identify metabolites but are unable to produce testable quantities of metabolites. Consequently, metabolite studies are delayed (a calculated risk) in the drug delivery process; having access to milligram quantities of drug metabolite permits resolution of many of the fundamental questions surrounding small molecule metabolism. The biomimetic technology speeds up metabolite studies to allow rapid improvement of the metabolic properties of drug candidates.” XenoTech’s Executive Vice President & COO, Jason Neat, further explains, “Combining XenoTech’s ability to effectively elucidate metabolite formation through biological processes with the ability to efficiently produce milligram quantities of metabolites of interest for further evaluation is a benefit we must bring to our clients. By pairing XenoTech’s in vitro DMPK expertise with HepatoChem’s innovative platform, we are able to offer a tremendous and comprehensive solution to our customers for risk mitigation.”

The innovative technology uses biomimetic catalysts to mimic oxidative metabolism which synthesizes metabolites from the parent drug. The catalytic conditions are as selective as enzyme specificity achieved with microsomes or hepatocytes yet have the advantage of enabling metabolite production in milligram quantities. This unique system offers a highly competitive, higher-yield, cost-effective alternative to biological metabolite synthesis, facilitating knowledge early in the development process for informed program decision-making. Researchers around the world will benefit from this synergistic pairing of XenoTech’s distinguished expertise and holistic approach to drug metabolism research with HepatoChem’s unique, effective and efficient biomimetic oxidation platform. Biomimetic metabolite synthesis is now offered as both a service, with the work performed by the expert scientists at XenoTech and HepatoChem or for in-house work as a product, allowing customers the freedom to synthesize metabolites in their own laboratories via the BMO™ Kit.
_______________________________________________________________________

About XenoTech
XenoTech, LLC is a global Contract Research Organization with unparalleled experience and expertise in evaluating drug candidates, nutraceuticals, cosmetics, food additives and other compounds widely known as xenobiotics, substrates, inhibitors and inducers of cytochrome P450, UGT and other drug metabolizing enzymes and drug transporters. The company offers a variety of in vitro and in vivo safety assessment studies for drug candidate evaluation, as well as an extensive selection of products for drug metabolism research. XenoTech’s product selection includes a wide-range of high quality standard reagents, from subcellular fractions and hepatocytes to recombinant enzymes, substrates and metabolites. The company can also prepare and deliver custom-designed products and services in respnose to client requests. For additional information, please refer to the company’s website at www.xenotechllc.com or call (913) 438-7450.

About HepatoChem
HepatoChem, Inc. of Beverly, Massachusetts was founded in 2008, is a life science company that has developed its technology platform through a partnership with Princeton University. HepatoChem focuses on early stage development with a game-changing, proprietary chemistry platform that enables fast and cost-effective metabolite production from bioactive small molecules. The HepatoChem technology enables assessment of critical metabolite and toxicity issues early in the R&D continuum, reducing the risk of failure in clinical development of drug candidates. For more information, visit www.hepatochem.com

HepatoChem at the Drug Discovery & Therapy World Congress 2014

HepatoChem will be attending the Drug Discovery & Therapy World Congress 2014 from June 16 – June 19 in Boston MA. The event will be held at the Hynes Convention Center located at 900 Boylston Street. Be sure to stop by and visit us at booth B6!

HepatoChem at the Massachusetts CRO/CMO Symposium

crocmo_email_header_2_

HepatoChem will be attending the Massachusetts CRO/CMO Symposium on Monday May 5 2014. The event will be held at the Burlington Marriott at 1 Burlington Road, Burlington MA. Be sure to stop by and visit us!

HepatoChem at the New Jersey DMDG

NJACS-atom-logo-44x2191HepatoChem will be attending the New Jersey Drug Metabolism Discussion Group Spring Symposium on May 1, 2014 at The Palace at Somerset Park in Somerset, NJ. Be sure to visit us to hear about our latest technologies!

HepatoChem, Inc. Designs Innovative Tools for the Life Sciences Industry

HepatoChem has developed extensive capabilities to quickly survey organo-metallic chemistry systems and design innovative tools for the pharmaceutical industry. It has most recently commercialized the BMO (BioMimetic Oxidation) Kit, which utilizes rapid one step biomimetic chemistry to generate useful quantities of drug candidate metabolites.  Applying a similar developmental approach, HepatoChem is now providing unique tools for the instant and flexible diversification of biologically active small molecules. These tools are largely centered on fluorination chemistry. HepatoChem is currently working with Vertex, a local biotech based in Boston, MA, to develop tools to allow for fast discovery of fluorinated analogues of small molecules, which Vertex scientists will employ in their own projects.

HepatoChem Co-founder and President Marc Bazin stated “Our work with Vertex is an extraordinary opportunity to demonstrate the versatility of HepatoChem’s platform. We are all committed to the development of innovative tools, such as chemical diversification kits, for companies that are seeking to discover and develop new medicines. “

About HepatoChem, Inc.

Founded in 2008, HepatoChem is an early-stage company that offers innovative services and products to the pharmaceutical industry. Our core expertise is organo-metallic catalysis and high-throughput compound analysis. HepatoChem received the Accelerator Loan from Mass Life Sciences Center in 2012 and is located in Beverly, MA at NorthShore InnoVentures (NSIV).

Contact

HepatoChem, Inc.

100 Cummings Center, Suite 424J

Beverly, MA 01915

Phone: (617) 500-5285

Fax: (617) 274-0827

HepatoChem mentioned in recent BMCL Digest article

HepatoChem is mentioned in a recent Bioorganic & Medicinal Chemistry Letters Digest article entitled, ‘Emerging technologies for metabolite generation and structural diversification‘. Be sure to check out the article at www.sciencedirect.com !

Cusack, Kevin P.; Vasudevan, Anil. Emerging technologies for metabolite generation and structural diversification. Bioorganic & Medicinal Chemistry Letters 23, 2013, 5471–5483.

HepatoChem at the Boston-PBSS

HepatoChem will be attending Boston Pharmaceutical & BioScience Society Workshop in Cambridge on Friday October 25th. Be sure to stop by and visit our booth!

HepatoChem at the International ISSX Meeting in Toronto

ISSX Toronto Meeting

HepatoChem will be attending The 10th International ISSX Meeting in Toronto from September 29th to October 2nd to unveil our new BMO Kit. Be sure to stop by and visit us at booth 505!

North Shore InnoVentures provides more than just lab and office space

In Salem News

BEVERLY — Early stage life sciences and “cleantech” companies that are part of the nonprofit business incubator North Shore InnoVentures are benefiting not only from reduced rates for lab and office space, but from the advice and networking it offers.

“To be successful, you can’t do it yourself,” said AdvaStim co-founder and Chief Technology Officer Barry Yomtov, whose medical device startup was one of the first to join North Shore InnoVentures.

“Networking is the biggest part,” said Martha Farmer, president and CEO of North Shore InnoVentures.

see more http://www.salemnews.com/business/x1525001303/Helping-startups-find-success

 

 

Reactive Metabolites Symposium

The 2nd Mitigation Strategies for Reactive Metabolites is the only meeting dedicated to helping you implement more effective risk assessment strategies for reactive metabolites in your organization and truly minimize the attrition of your pipeline.

November 27-29, 2012 at Revere Hotel, Boston, MA

http://reactive-metabolites.com/